Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Innovation Council · Running

NTX1088 First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care

Coordinator
Nectin Therapeutics Ltd, Israel
Runs
1 August 2024 to 31 January 2028
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101164808

What the project is doing

In the project's own words, from its summary on CORDIS.

Nectin Therapeutics (NectinTx) is a venture-backed company with a top-notch team focused on innovative therapeutic options for cancer patients. To address the limitations of available therapies, the company has developed a diverse pipeline of antibodies that overcome immune inhibitory pathways deployed by the tumours. NTX1088 is a monoclonal antibody that binds human poliovirus receptor (PVR) and activates patient’s immune system to fight cancer through a triple mechanism of action never demonstrated before.

A comprehensive preclinical dataset was generated to show the robust antitumor activity of NTX1088 in vitro and in vivo. Following IND approval and strong backing from key opinion leaders, Phase I clinical trial has commenced, aimed to enrol patients with solid tumours. The project will accelerate the clinical development of NTX1088 towards a novel therapy on the €80 billion immune-oncology drug market, resulting in better outcomes for patients and reduced societal and economic burden associated with cancer.

Who is involved

OrganisationCityCountryRole
Nectin Therapeutics LtdJerusalemIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI